Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment

Jennifer McNeely, Andrea B Troxel, Hillary V Kunins, Donna Shelley, Joshua D Lee, Alexander Walley, Zoe M Weinstein, John Billings, Nichola J Davis, Roopa Kalyanaraman Marcello, Bruce R Schackman, Charles Barron, Luke Bergmann, Jennifer McNeely, Andrea B Troxel, Hillary V Kunins, Donna Shelley, Joshua D Lee, Alexander Walley, Zoe M Weinstein, John Billings, Nichola J Davis, Roopa Kalyanaraman Marcello, Bruce R Schackman, Charles Barron, Luke Bergmann

Abstract

Background: Treatment for opioid use disorder (OUD) is highly effective, yet it remains dramatically underutilized. Individuals with OUD have disproportionately high rates of hospitalization and low rates of addiction treatment. Hospital-based addiction consult services offer a potential solution by using multidisciplinary teams to evaluate patients, initiate medication for addiction treatment (MAT) in the hospital, and connect patients to post-discharge care. We are studying the effectiveness of an addiction consult model [Consult for Addiction Treatment and Care in Hospitals (CATCH)] as a strategy for engaging patients with OUD in treatment as the program rolls out in the largest municipal hospital system in the US. The primary aim is to evaluate the effectiveness of CATCH in increasing post-discharge initiation and engagement in MAT. Secondary aims are to assess treatment retention, frequency of acute care utilization and overdose deaths and their associated costs, and implementation outcomes.

Methods: A pragmatic trial at six hospitals, conducted in collaboration with the municipal hospital system and department of health, will be implemented to study the CATCH intervention. Guided by the RE-AIM evaluation framework, this hybrid effectiveness-implementation study (Type 1) focuses primarily on effectiveness and also measures implementation outcomes to inform the intervention's adoption and sustainability. A stepped-wedge cluster randomized trial design will determine the impact of CATCH on treatment outcomes in comparison to usual care for a control period, followed by a 12-month intervention period and a 6- to 18-month maintenance period at each hospital. A mixed methods approach will primarily utilize administrative data to measure outcomes, while interviews and focus groups with staff and patients will provide additional information on implementation fidelity and barriers to delivering MAT to patients with OUD.

Discussion: Because of their great potential to reduce the negative health and economic consequences of untreated OUD, addiction consult models are proliferating in response to the opioid epidemic, despite the absence of a strong evidence base. This study will provide the first known rigorous evaluation of an addiction consult model in a large multi-site trial and promises to generate knowledge that can rapidly transform practice and inform the potential for widespread dissemination of these services.

Trial registration: NCT03611335.

Keywords: (MeSH term) Consultation; (MeSH term) Inpatients; (MeSH term) Opioid substitution treatment; Addiction; Consult service; Hospitalization; Opioid use disorder; Protocol; Substance use disorder.

Figures

Fig. 1
Fig. 1
RE-AIM evaluation framework
Fig. 2
Fig. 2
Stepped-wedge design with 6 sites

References

    1. US Department of Health and Human Services (HHS), Office of the Surgeon General. Facing Addiction in America. The surgeon general’s report on alcohol, drugs, and health. Washington, DC;2016.
    1. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths-United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445–1452. doi: 10.15585/mmwr.mm655051e1.
    1. US Department of Health and Human Services. The Opioid Epidemic: By the Numbers 2016. . Accessed 21 May 2017.
    1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths-United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382. doi: 10.15585/mmwr.mm6450a3.
    1. National Institute on Drug Abuse. Overdose Death Rates 2018. . Accessed 7 Sept 2018.
    1. Nolan ML, Tuazon E, Blachman-Forshay J, Paone D. Unintentional drug poisoning (overdose) deaths in New York City, 2000 to 2017. New York City Department of Health and Mental Hygiene: Epi Data Brief (104);2018. . Accessed 21 Jan 2019.
    1. Healing NYC: Preventing overdoses, saving lives 2017. .
    1. Englander H, Weimer M, Solotaroff R, Nicolaidis C, Chan B, Velez C, et al. Planning and designing the improving addiction care team (IMPACT) for hospitalized adults with substance use disorder. J Hos Med. 2017;12(5):339–342. doi: 10.12788/jhm.2736.
    1. Wakeman SE, Metlay JP, Chang Y, Herman GE, Rigotti NA. Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity. J Gen Intern Med. 2017;32:909. doi: 10.1007/s11606-017-4077-z.
    1. Trowbridge P, Weinstein ZM, Kerensky T, Roy P, Regan D, Samet JH, et al. Addiction consultation services—linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat. 2017;79:1–5. doi: 10.1016/j.jsat.2017.05.007.
    1. Murphy MK, Chabon B, Delgado A, Newville H, Nicolson SE. Development of a substance abuse consultation and referral service in an academic medical center: challenges, achievements and dissemination. J Clin Psychol Med Set. 2009;16:77–86. doi: 10.1007/s10880-009-9149-8.
    1. Owens PL, Barrett ML, Weiss AJ, Washington RE, Kronick R. Hospital inpatient utilization related to opioid overuse among adults, 1993–2012: statistical brief#177. Rockville: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs; 2006.
    1. McNeely J, Gourevitch MN, Paone D, Shah S, Wright S, Heller D. Estimating the prevalence of illicit opioid use in New York City using multiple data sources. BMC Public Health. 2012;12:443. doi: 10.1186/1471-2458-12-443.
    1. Naeger S, Mutter R, Ali MM, Mark T, Hughey L. Post-discharge treatment engagement among patients with an opioid-use disorder. J Subst Abuse Treat. 2016;69:64–71. doi: 10.1016/j.jsat.2016.07.004.
    1. Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103(9):1484–1492. doi: 10.1111/j.1360-0443.2008.02249.x.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;8(3):Cd002209.
    1. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi: 10.1136/bmj.j1550.
    1. National Institute on Drug Abuse. Expanding medication assisted treatment for opioid use disorders in the context of the SAMHSA opioid STR Grants (RFA-DA-18-005) 2017. . Accessed 28 May 2017.
    1. Park-Lee E, Lipari RN, Hedden SL, Copello EAP, Kroutil LA. Receipt of services for substance use and mental health issues among adults: results from the 2015 national survey on drug use and health;2016. NSDUH Data Review. . Accessed 28 May 2017.
    1. Glass JE, Hamilton AM, Powell BJ, Perron BE, Brown RT, Ilgen MA. Specialty substance use disorder services following brief alcohol intervention: a meta-analysis of randomized controlled trials. Addiction. 2015;110(9):1404–1415. doi: 10.1111/add.12950.
    1. Glass JE, Hamilton AM, Powell BJ, Perron BE, Brown RT, Ilgen MA. Revisiting our review of screening, brief intervention and referral to treatment (SBIRT): meta-analytical results still point to no efficacy in increasing the use of substance use disorder services. Addiction. 2016;111(1):181–183. doi: 10.1111/add.13146.
    1. Saitz R, Cheng DM, Winter M, Kim TW, Meli SM, Allensworth-Davies D, et al. Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. JAMA J Am Med Assoc. 2013;310(11):1156–1167. doi: 10.1001/jama.2013.277609.
    1. Roy-Byrne P, Bumgardner K, Krupski A, Dunn C, Ries R, Donovan D, et al. Brief intervention for problem drug use in safety-net primary care settings a randomized clinical trial. JAMA J Am Med Assoc. 2014;312(5):492–501. doi: 10.1001/jama.2014.7860.
    1. D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA J Am Med Assoc. 2015;313(16):1636–1644. doi: 10.1001/jama.2015.3474.
    1. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–1376. doi: 10.1001/jamainternmed.2014.2556.
    1. Aszalos R, McDuff DR, Weintraub E, Montoya I, Schwartz R. Engaging hospitalized heroin-dependent patients into substance abuse treatment. J Subst Abuse Treat. 1999;17(1–2):149–158. doi: 10.1016/S0740-5472(98)00075-0.
    1. Pecoraro A, Horton T, Ewen E, Becher J, Wright PA, Silverman B, et al. Early data from project engage: a program to identify and transition medically hospitalized patients into addictions treatment. Addict Sci Clin Pract. 2012;7:20. doi: 10.1186/1940-0640-7-20.
    1. Shanahan CW, Beers D, Alford DP, Brigandi E, Samet JH. A transitional opioid program to engage hospitalized drug users. J Gen Intern Med. 2010;25:803–808. doi: 10.1007/s11606-010-1311-3.
    1. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–1327. doi: 10.2105/AJPH.89.9.1322.
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217–226. doi: 10.1097/MLR.0b013e3182408812.
    1. Glasgow RE, Lichtenstein E, Marcus AC. Why don’t we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003;93(8):1261–1267. doi: 10.2105/AJPH.93.8.1261.
    1. March J, Kraemer HC, Trivedi M, Csernansky J, Davis J, Ketter TA, et al. What have we learned about trial design from NIMH-funded pragmatic trials? Neuropsychopharmacology. 2010;35(13):2491–2501. doi: 10.1038/npp.2010.115.
    1. Tosh G, Soares-Weiser K, Adams CE. Pragmatic vs explanatory trials: the pragmascope tool to help measure differences in protocols of mental health randomized controlled trials. Dialogues Clin Neurosci. 2011;13(2):209–215.
    1. Selby P, Brosky G, Oh PI, Raymond V, Ranger S. How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial. BMC Med Res Methodol. 2012;12(1):101. doi: 10.1186/1471-2288-12-101.
    1. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. doi: 10.1136/bmj.h391.
    1. Brown CH, Curran G, Palinkas LA, Aarons GA, Wells KB, Jones L, et al. An overview of research and evaluation designs for dissemination and implementation. Annu Rev Public Health. 2017;38:1–22. doi: 10.1146/annurev-publhealth-031816-044215.
    1. Barker D, McElduff P, D’Este C, Campbell MJ. Stepped wedge cluster randomised trials: a review of the statistical methodology used and available. BMC Med Res Methodol. 2016;16:69. doi: 10.1186/s12874-016-0176-5.
    1. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. doi: 10.1136/bmj.a2390.
    1. Substance Abuse and Mental Health Services Administration (SAMHSA). Buprenorphine Waiver management. . Accessed 7 Sept 2018.
    1. Office of Alcoholism and Substance Abuse Services (OASAS), Certified peer advocate. . Accessed 22 May 2017.
    1. Harocopos A, Allen B, Paone D. Circumstances and contexts of heroin initiation following non-medical opioid analgesic use in New York City. Int J Drug Policy. 2016;28:106–112. doi: 10.1016/j.drugpo.2015.12.021.
    1. Paone D, Tuazon E, Kattan J, Nolan ML, O’Brien DB, Dowell D, et al. Decrease in rate of opioid analgesic overdose deaths—Staten Island, New York City, 2011–2013. MMWR Morb Mortal Wkly Rep. 2015;64(18):491–494.
    1. Paone D, Tuazon E, Stajic M, Sampson B, Allen B, Mantha S, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Depend. 2015;155:298–301. doi: 10.1016/j.drugalcdep.2015.08.007.
    1. Siegler A, Tuazon E, Bradley O’Brien D, Paone D. Unintentional opioid overdose deaths in New York City, 2005–2010: a place-based approach to reduce risk. Int J Drug Policy. 2014;25(3):569–574. doi: 10.1016/j.drugpo.2013.10.015.
    1. Mertens JR, Chi FW, Weisner CM, Satre DD, Ross TB, Allen S, et al. Physician versus non-physician delivery of alcohol screening, brief intervention and referral to treatment in adult primary care: the ADVISe cluster randomized controlled implementation trial. Addict Sci Clin Pract. 2015;10(1):26. doi: 10.1186/s13722-015-0047-0.
    1. NCQA. HEDIS Measures. . Accessed 21 May 2017.
    1. NCQA. HEDIS and Quality Compass. . Accessed 21 May 2017.
    1. Harris AH, Humphreys K, Finney JW. Veterans affairs facility performance on Washington circle indicators and case mix-adjusted effectiveness. J Subst Abuse Treat. 2007;33(4):333–339. doi: 10.1016/j.jsat.2006.12.015.
    1. NCQA. Healthcare Effectiveness Data and Information Set (HEDIS). Summary of Measures, Product Lines and Changes. 2018. . Accessed 21 Jan 2019.
    1. O’Toole TP, Conde-Martel A, Young JH, Price J, Bigelow G, Ford DE. Managing acutely ill substance-abusing patients in an integrated day hospital outpatient program: medical therapies, complications, and overall treatment outcomes. J Gen Intern Med. 2006;21(6):570–576. doi: 10.1111/j.1525-1497.2006.00398.x.
    1. Lee CS, Liebschutz JM, Anderson BJ, Stein MD. Hospitalized opioid-dependent patients: exploring predictors of buprenorphine treatment entry and retention after discharge. Am J Addict/Am Acad Psychiatr Alcohol Addict. 2017;26:667. doi: 10.1111/ajad.12533.
    1. Chutuape MA, Katz EC, Stitzer ML. Methods for enhancing transition of substance dependent patients from inpatient to outpatient treatment. Drug Alcohol Depend. 2001;61(2):137–143. doi: 10.1016/S0376-8716(00)00133-2.
    1. D’Onofrio G, Degutis LC. Integrating project ASSERT: a screening, intervention, and referral to treatment program for unhealthy alcohol and drug use into an urban emergency department. Acad Emerg Med. 2010;17(8):903–911. doi: 10.1111/j.1553-2712.2010.00824.x.
    1. Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA J Am Med Assoc. 2016;316(2):156–170. doi: 10.1001/jama.2016.8914.
    1. Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003;348(18):1786–1795. doi: 10.1056/NEJMra020617.
    1. Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278–287. doi: 10.1080/10550887.2012.694603.
    1. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer; 1991.
    1. Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict/Am Acad Psychiatr Alcohol Addict. 2008;17(2):116–120. doi: 10.1080/10550490701860971.
    1. Bhatraju EP, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, et al. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract. 2017;12(1):7. doi: 10.1186/s13722-017-0072-2.
    1. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK general practice research database. BMJ. 2010;341:c5475. doi: 10.1136/bmj.c5475.
    1. Cousins G, Boland F, Courtney B, Barry J, Lyons S, Fahey T. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction. 2016;111(1):73–82. doi: 10.1111/add.13087.
    1. Evans E, Li L, Min J, Huang D, Urada D, Liu L, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006–10. Addiction. 2015;110(6):996–1005. doi: 10.1111/add.12863.
    1. Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12. Health Aff (Millwood) 2016;35(5):832–837. doi: 10.1377/hlthaff.2015.1424.
    1. Walley AY, Paasche-Orlow M, Lee EC, Forsythe S, Chetty VK, Mitchell S, et al. Acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis. J Addict Med. 2012;6(1):50–56. doi: 10.1097/ADM.0b013e318231de51.
    1. Lynch FL, McCarty D, Mertens J, Perrin NA, Green CA, Parthasarathy S, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014;9:16. doi: 10.1186/1940-0640-9-16.
    1. Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902. doi: 10.1111/add.13270.
    1. Stetler CB, Legro MW, Wallace CM, Bowman C, Guihan M, Hagedorn H, et al. The role of formative evaluation in implementation research and the QUERI experience. J Gen Intern Med. 2006;21(Suppl 2):S1–S8. doi: 10.1007/s11606-006-0267-9.
    1. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci IS. 2009;4:50. doi: 10.1186/1748-5908-4-50.
    1. Powell BJ, Proctor EK, Glass JE. A systematic review of strategies for implementing empirically supported mental health interventions. Res Soc Work Pract. 2014;24(2):192–212. doi: 10.1177/1049731513505778.
    1. Kleinbaum DG, Kupper LL, Nizam A, Miller KE. Applied regression analysis and other multivariable methods. 4. Pacific Grove: Duxbury Press; 2008.
    1. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125–137. doi: 10.1093/oxfordjournals.aje.a115101.
    1. United States Department of Labor, Bureau of Labor Statistics. . Accessed 21 Jan 2019.
    1. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. 2. New York: Oxford University Press; 2016.
    1. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi: 10.1056/NEJMp1405158.
    1. Muhr T. ATLAS. ti (Version 6.0. 15) Berlin: Scientific Software Development; 2012.
    1. Kim HM, Smith EG, Stano CM, Ganoczy D, Zivin K, Walters H, et al. Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv Res. 2012;12:18. doi: 10.1186/1472-6963-12-18.
    1. Steele LS, Glazier RH, Lin E, Evans M. Using administrative data to measure ambulatory mental health service provision in primary care. Med Care. 2004;42(10):960–965. doi: 10.1097/00005650-200410000-00004.
    1. Valenstein M, Ritsema T, Green L, Blow FC, Mitchinson A, McCarthy JF, et al. Targeting quality improvement activities for depression. Implications of using administrative data. J Family Pract. 2000;49(8):721–728.
    1. Walley AY, Farrar D, Cheng DM, Alford DP, Samet JH. Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue. J Gen Intern Med. 2009;24(9):1007–1011. doi: 10.1007/s11606-009-1043-4.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever